Fierce Pharma
APRIL 19, 2023
Goodbye, original COVID-19 vaccines: FDA updates shot guidance, pulls monovalent authorizations zbecker Wed, 04/19/2023 - 11:04
PharmaVoice
APRIL 18, 2023
How an “international” childhood sent Dr. José Trevejo, Tarsus’s chief medical officer, on a mission to fight infectious diseases.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Medgadget
APRIL 18, 2023
Researchers at MIT have developed lipid nanoparticles that are highly efficient at delivering mRNA therapies to lung cells. Getting therapeutic agents into the lungs can be challenging, but there are a variety of medical challenges that could be addressed by efficiently targeting lung cells with nanoparticle technologies. These latest particles are highly efficient at delivering mRNA which can then encode therapeutically useful proteins in the lungs.
MedCity News
APRIL 17, 2023
Innovaccer launched a new product called Sara, a conversational AI assistant designed to help executives at health systems and payers make better use of their data. It allows executives can ask complex questions about their organization’s patients or members and get immediate answers on clinical, financial or operational metrics.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
APRIL 21, 2023
In heavyweight obesity fight, Eli Lilly launches Mounjaro head-to-head trial against Novo Nordisk's Wegovy aliu Fri, 04/21/2023 - 22:35
Pharmaceutical Technology
APRIL 19, 2023
The US Food and Drug Administration (FDA) has made changes to the emergency use authorisations (EUAs) of the Pfizer -BioNTech and Moderna bivalent mRNA Covid-19 vaccines. The latest amendment aims to simplify the vaccination schedule for most people. The changes mean that the current bivalent vaccines for the original and Omicron BA.4/BA.5 strains can now be utilised for all doses administered to those aged six months and above.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
APRIL 21, 2023
By combining in-home and virtual care, we can meet patients literally where they are. More importantly, we can improve outcomes, reduce costs and help patients get back to a normal life while giving therapists the flexibility and opportunity to provide more customized care for their patients.
Fierce Pharma
APRIL 20, 2023
'The Top Line': How Pfizer became the first in Big Pharma history to break $100B in sales, plus this week's headlines tcarey Thu, 04/20/2023 - 14:46
PharmaVoice
APRIL 21, 2023
Peter Kirk’s marathon story of inspiration and perseverance.
Pharmaceutical Technology
APRIL 19, 2023
SAB Biotherapeutics has received breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for SAB-176, an investigational immunotherapy to treat influenza. The newly granted status allows SAB to speed up the development and review of SAB-176, which is currently being studied for use in post-exposure prophylaxis for Type A and Type B influenza in high-risk patients, including those with anti-viral resistant strains.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
APRIL 18, 2023
Glen Tullman — CEO of care navigation company Transcarent, as well as former CEO of Allscripts and Livongo — discussed what he thinks the future of healthcare will look like during the HIMSS conference in Chicago. He laid out five predictions, including an increased focus on consumer expectations and more investment in AI.
Fierce Pharma
APRIL 17, 2023
In Pfizer's $43B acquisition of Seagen, the biotech's patience paid off kdunleavy Mon, 04/17/2023 - 11:34
European Pharmaceutical Review
APRIL 17, 2023
Merck & Co. Inc has agreed to acquire Prometheus Biosciences for $10.8 billion. The agreement is set to help advance PRA023, a novel humanised monoclonal antibody (mAb), developed by Prometheus. Its chosen indications are ulcerative colitis (UC) and Crohn’s disease (CD) and other autoimmune conditions. Prometheus is a clinical-stage biotechnology company.
Pharmaceutical Technology
APRIL 21, 2023
Twist Bioscience and Astellas Pharma have entered a collaboration to help the latter to discover antibodies for immunotherapies. This is the third collaboration between the two companies. In May 2022, they signed a research partnership and exclusive option licence agreement for the development of antibodies to reduce tumour microenvironment-mediated immunosuppression.
MedCity News
APRIL 20, 2023
Health technologies are often built based on the “reference man” and frequently don’t take other demographics into account. It shouldn’t be this way, experts argued on a panel Thursday at the HIMSS 2023 conference.
Fierce Pharma
APRIL 18, 2023
Double whammy: Supreme Court slaps down separate bids from Novartis, Sanofi esagonowsky Tue, 04/18/2023 - 08:25
PharmExec
APRIL 17, 2023
J&J's Janssen Pharmaceutica NV collaborates with Pipeline Therapeutics in a $50 million licensing deal for oral MS drug PIPE-307, with potential earnings of up to $1 billion for Pipeline.
Pharmaceutical Technology
APRIL 17, 2023
Merck has signed a definitive agreement to buy clinical-stage biotechnology firm Prometheus Biosciences for $10.8bn, strengthening its immunology pipeline. The company will buy all of Prometheus Biosciences’ outstanding shares for $200 a share through a subsidiary. Prometheus Biosciences uses precision medicine to discover, develop and commercialise new therapeutic and companion diagnostic products to treat immune-mediated diseases.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
APRIL 20, 2023
Over the past 2 years, concerted efforts have been undertaken by policymakers and FDA’s Oncology Center of Excellence to mitigate risks and improve the transparency of the accelerated approval program. These actions are crucial to restoring public trust – trust that has suffered considerable erosion.
Fierce Pharma
APRIL 21, 2023
As Bayer's CEO switch nears, activist investor pushes harder for breakup, board changes fkansteiner Fri, 04/21/2023 - 10:25
PharmaTimes
APRIL 19, 2023
Link-up has already delivered data showing the promise of nanoparticle-formulated doggybone DNA
European Pharmaceutical Review
APRIL 21, 2023
Imbruvica ® (ibrutinib) plus venetoclax has been recommended as an option for untreated chronic lymphocytic leukaemia (CLL) in adults by the National Institute for Health and Care Excellence (NICE). Ibrutinib is a tyrosine kinase inhibitor (TKI) therapy. By blocking Bruton’s tyrosine kinase (BTK), which is needed by cancer cells to multiply and spread, ibrutinib could help stop them from growing and dividing.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
APRIL 20, 2023
Health disparities are often a result of other socioeconomic factors like housing and nutrition. Because of this, the healthcare industry needs to work with other sectors to improve health equity, said Hans Kluge, regional director for Europe of the World Health Organization, at the HIMSS 2023 conference.
Fierce Pharma
APRIL 20, 2023
What spurred Lilly, Novo and Sanofi to slash insulin prices?
Pharmaceutical Technology
APRIL 21, 2023
The US Food and Drug Administration (FDA) has pushed quizartinib’s Prescription Drug User Fee Act (PDUFA) date in newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) for the review of updates of Risk Evaluation and Mitigation Strategies (REMS) included in the application. The PDUFA date was extended by three months to July 24, based on an April 20 company announcement.
Copyright Clearance Center
APRIL 21, 2023
The post In London, Publishing Confronts AI appeared first on Copyright Clearance Center.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
MedCity News
APRIL 19, 2023
With AI being so new, there are some best practices for companies to follow when bringing it into healthcare. This includes partnerships and understanding the shortcomings of AI, several experts said during a session at the HIMSS 2023 conference.
Fierce Pharma
APRIL 20, 2023
Fierce Pharma Asia—Carvykti's massive myeloma win; BeiGene's PD-1 comeback aliu Thu, 04/20/2023 - 15:00
Pharmaceutical Technology
APRIL 20, 2023
Chinese firm Hasten Biopharmaceutic has raised $315m for business development of its pipeline assets in a financing round co-led by Singapore-based CBC Group and Abu Dhabi sovereign wealth fund Mubadala Investment, The funding round was supported by additional institutional investors. Hasten will also use the proceeds from the round to fund future acquisitions.
Copyright Clearance Center
APRIL 20, 2023
The post 10 Questions to Ask When Searching for a Corporate Literature Management Solution appeared first on Copyright Clearance Center.
Expert insights. Personalized for you.
364 
Let's personalize your content